Huayao Jiexin

Huayao Jiexin (Beijing) Medical Technology is a pioneering Chinese biotechnology company focused on the development of innovative radiopharmaceuticals for the integrated diagnosis and treatment of cancer. Founded in 2022 by Professor Wang Fan of Peking University and CEO Zhang Yong, the company leverages advanced isotope labeling and targeting technologies to create a precision medicine platform. Its lead candidate, HJ-001, is a targeted tumor imaging agent that focuses on integrin αvβ3, providing a broad-spectrum diagnostic tool for solid tumors. The company is actively developing a pipeline of theranostic pairs, aiming to bridge the gap between precise molecular imaging and targeted radionuclide therapy. Headquartered in Beijing's Zhongguancun Life Science Park, Huayao Jiexin is supported by prominent investors including Hillhouse GL Ventures and Future Capital.